FDA approved Sunharbo (asundexian) 50 mg tablets on November 9 to reduce stroke risk in a defined group of adults, in combination with antiplatelet therapy. The agency says it is the first approved factor XIa inhibitor.
Who the approval covers
The indication covers adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, often called a TIA. In the stroke group, the clot did not originate in the heart.
FDA explicitly says Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. The approval therefore does not extend to every person who has had a stroke or has a risk factor for one.
The approval was granted to Bayer HealthCare Pharmaceuticals.
What FDA reports about the trial
The agency's announcement describes OCEANIC-STROKE as a randomized, double-blind, placebo-controlled phase 3 study involving 12,327 adults. Participants were assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy.
FDA says the once-daily 50 mg treatment reduced ischemic-stroke risk by 26% compared with placebo, over a median treatment period of 14.2 months. That is a relative comparison, not a 26-percentage-point reduction. The release does not provide absolute event rates from which to calculate an individual patient's benefit.
The bleeding limits
FDA reports a similar overall major-bleeding rate between the treatment groups, but increased major bleeding with Sunharbo among patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was also more common with Sunharbo than placebo.
The announcement says Sunharbo is not recommended for patients with moderate or severe liver impairment, or for concurrent use with medicines that are combined P-gp and strong CYP3A4 inducers, such as carbamazepine, because they may reduce its effectiveness.
Those restrictions accompany the approval. The release is an agency summary, rather than the full prescribing information or an assessment of which treatment is appropriate for an individual patient.

